Presentation Title

Crystallization, enzymatic, and inhibitory studies of M. tuberculosis-encoded methyltransferase to assess the importance in pathogenesis

Faculty Mentor

Donald R. Ronning

Start Date

23-11-2019 8:00 AM

End Date

23-11-2019 8:45 AM

Location

65

Session

poster 1

Type of Presentation

Poster

Subject Area

biological_agricultural_sciences

Abstract

The World Health Organization estimates that there are 10 million cases of tuberculosis (TB) cases each year. Caused by the bacterium Mycobacterium tuberculosis, TB is highly contagious and requires 6-9 months to treat. The demand for improved drugs for treating TB has increased due to the rise in TB rates caused by drug-resistance strains. The specific objectives of this project are to clone, express, purify, assay, and determine the X-ray crystal structure of recombinant Rv1405 to afford further characterization of the enzyme function in mycobacteria. Differential Scanning Fluorimetry (DSF) was employed to screen various inhibitor libraries to identify compounds that bind Rv1405. To assess the inhibitory activity of the compounds identified in the DSF screening, enzymatic studies were performed. Although knowledge of the Rv1405 methyl acceptor is lacking, initial enzymatic studies using a panel of different chemotypes as methyl acceptors in an Rv1405 catalyzed reaction showed that Tris functions as a methyl acceptor in the enzymatic assay and can be used as a surrogate substrate in inhibitor-screening experiments until the biological substrate is identified. Structural studies have been initiated through Rv1405 crystallization experiments. Initial crystals diffracting to 8 Åresolution have been obtained and are currently being optimize to improve diffraction data quality. Obtaining the X-ray crystal structure will provide crucial information to infer the identity of the methyl acceptor, the mode of methyl acceptor binding, and advance drug development of new TB drugs that target Rv1405.

This document is currently not available here.

Share

COinS
 
Nov 23rd, 8:00 AM Nov 23rd, 8:45 AM

Crystallization, enzymatic, and inhibitory studies of M. tuberculosis-encoded methyltransferase to assess the importance in pathogenesis

65

The World Health Organization estimates that there are 10 million cases of tuberculosis (TB) cases each year. Caused by the bacterium Mycobacterium tuberculosis, TB is highly contagious and requires 6-9 months to treat. The demand for improved drugs for treating TB has increased due to the rise in TB rates caused by drug-resistance strains. The specific objectives of this project are to clone, express, purify, assay, and determine the X-ray crystal structure of recombinant Rv1405 to afford further characterization of the enzyme function in mycobacteria. Differential Scanning Fluorimetry (DSF) was employed to screen various inhibitor libraries to identify compounds that bind Rv1405. To assess the inhibitory activity of the compounds identified in the DSF screening, enzymatic studies were performed. Although knowledge of the Rv1405 methyl acceptor is lacking, initial enzymatic studies using a panel of different chemotypes as methyl acceptors in an Rv1405 catalyzed reaction showed that Tris functions as a methyl acceptor in the enzymatic assay and can be used as a surrogate substrate in inhibitor-screening experiments until the biological substrate is identified. Structural studies have been initiated through Rv1405 crystallization experiments. Initial crystals diffracting to 8 Åresolution have been obtained and are currently being optimize to improve diffraction data quality. Obtaining the X-ray crystal structure will provide crucial information to infer the identity of the methyl acceptor, the mode of methyl acceptor binding, and advance drug development of new TB drugs that target Rv1405.